Gilead Sciences, Inc. (GILD) Stake Lowered by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 502,684 shares of the biopharmaceutical company’s stock after selling 110,738 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Gilead Sciences were worth $38,249,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC grew its holdings in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Webster Bank N. A. grew its holdings in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences during the first quarter valued at approximately $143,000. Finally, Welch Group LLC grew its holdings in shares of Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 252 shares during the last quarter. 74.28% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) opened at 75.99 on Tuesday. The stock has a market capitalization of $99.24 billion, a PE ratio of 8.25 and a beta of 1.14. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The firm has a 50 day moving average of $81.76 and a 200-day moving average of $73.26.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 earnings per share. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.76 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.74%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.
TRADEMARK VIOLATION NOTICE: This article was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2017/10/31/gilead-sciences-inc-gild-stake-lowered-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma.html.
GILD has been the topic of a number of recent analyst reports. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. Robert W. Baird reiterated an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $85.68.
In other news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the sale, the executive vice president now directly owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 358,486 shares of company stock valued at $29,637,678. 1.30% of the stock is currently owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.